Recombinant E. coli for Anaerobic L-Valine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing L-valine through fermentation are limited by intracellular regulatory networks, requiring energy-intensive aerobic conditions and relying on plasmid-borne gene overexpression, which increases costs and risks of plasmid loss, while anaerobic fermentation for amino acid production has not been achieved for L-valine.
Innovation Solution
A recombinant Escherichia coli strain is developed with enhanced amino acid dehydrogenase activity and activated Entner-Doudoroff pathway, allowing for balanced reducing power under anaerobic conditions, enabling one-step anaerobic fermentation of L-valine by integrating specific genes and regulatory elements into the genome, eliminating the need for antibiotics and reducing energy consumption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional mutagenesis is used to obtain L-valine producing strains, then L-valine production is achieved, but the process is random, has unclear genetic background, produces by-products, and is difficult to modify further
Solution Approach 1:
The patent segments the metabolic pathway into distinct functional modules: acetolactate synthase (ALS) for pyruvate condensation, dihydroxy acid dehydratase (ILV D) for dehydration, and amino acid dehydrogenase (AAD) for reductive amination. Each module is independently engineered and optimized, allowing systematic improvement of L-valine production without the randomness of traditional mutagenesis.
Solution Approach 2:
The patent performs preliminary genetic engineering to construct a standardized metabolic pathway framework before actual L-valine production. Key enzymes are pre-introduced and optimized in the strain, establishing a clear genetic background and controlled metabolic flux that eliminates the need for subsequent random mutagenesis and by-product formation.
2Quantity of substance
If aerobic fermentation is used for L-valine production, then high L-valine titer is achieved, but energy consumption increases and carbon sources are consumed by cell growth
Solution Approach 1:
The patent fundamentally changes the fermentation parameter from aerobic to anaerobic conditions. This parameter change shifts the metabolic pathway from respiratory metabolism to anaerobic metabolism, reducing energy consumption while maintaining high L-valine titer through optimized anaerobic enzyme activities and substrate utilization.
Solution Approach 2:
The patent converts the typically harmful effect of anaerobic conditions (which usually limit amino acid production) into a beneficial approach by specifically engineering anaerobic pathways and enzymes. The anaerobic metabolism is redesigned to favor L-valine production, turning a limitation into an advantage for reducing energy consumption and improving carbon efficiency.
3Productivity
If plasmid-borne gene overexpression is used to enhance enzyme activity, then L-valine production is improved, but antibiotic costs increase and plasmid loss risk increases
Solution Approach 1:
The patent extracts the plasmid carrier and antibiotic selection mechanisms from the gene expression system. Instead of using plasmids, the engineered enzymes are integrated directly into the chromosomal genome through stable integration. This eliminates plasmid loss risk and antibiotic requirements while maintaining high enzyme activity for L-valine production.
Solution Approach 2:
The patent implements self-service by using the cell's own chromosomal replication and expression machinery to maintain and propagate the engineered genes. The integrated genes are replicated passively during cell division without requiring external plasmid maintenance systems or antibiotic selection pressures, making the system self-sustaining and reliable.
4Stability of the object's composition
If feedback inhibition is present in the intracellular regulatory network, then metabolic control is maintained, but L-valine production capacity is greatly limited
Solution Approach 1:
The patent extracts and eliminates the feedback inhibition mechanism from the metabolic pathway. The engineered pathway uses alternative enzymes and regulatory mechanisms that do not subject to product inhibition, removing the constraint that limited L-valine production capacity while maintaining appropriate metabolic control through engineered promoters and regulatory elements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves high-yield, stable, and energy-efficient L-valine production under anaerobic conditions, reducing production costs and eliminating the need for antibiotics, with the recombinant strain capable of producing L-valine at high titers and yields.
Implementation Method 1
activated Entner-Doudoroff pathway, allowing for balanced reducing power under anaerobic conditions
Implementation Method 2
one-step anaerobic fermentation process
Data Source
AI summary
Related are a recombinant microorganism for producing L-valine, a construction method and an application thereof. Through enhancing amino acid dehydrogenase activity of L-valine fermentation strain, and/or activating an Entner-Doudoroff (ED) metabolic pathway, a problem in L-valine fermentation process that reducing power is unbalanced is solved, thereby the titer and yield of L-valine produced by Escherichia coli are improved, and L-valine was produced by one-step anaerobic fermentation.